Organoidsciences Ltd. (KOSDAQ:476040)

South Korea flag South Korea · Delayed Price · Currency is KRW
22,400
-300 (-1.32%)
At close: Apr 30, 2026
Market Cap147.52B
Revenue (ttm)2.41B +23.2%
Net Income-15.37B
EPS-2,517.00
Shares Out6.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,452
Average Volume85,992
Open22,750
Previous Close22,700
Day's Range22,250 - 23,300
52-Week Range20,250 - 52,000
Betan/a
RSI42.35
Earnings DateApr 10, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476040
Full Company Profile

Financial Performance

In 2025, Organoidsciences's revenue was 2.41 billion, an increase of 23.21% compared to the previous year's 1.95 billion. Losses were -15.37 billion, 36.6% more than in 2024.

Financial Statements